PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension

Eur Respir J. 2007 Jan;29(1):220-1. doi: 10.1183/09031936.00110006.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors
  • Carbolines / therapeutic use*
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Humans
  • Hypertension, Portal / drug therapy*
  • Hypertension, Pulmonary / drug therapy*
  • Male
  • Middle Aged
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Tadalafil

Substances

  • Carbolines
  • Phosphodiesterase Inhibitors
  • Tadalafil
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • PDE5A protein, human